Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial
Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...
pharmaphorum18h
Pharma’s climate change vulnerability and opportunity
As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.